Abstract:Abstract Background Metabolism reprogramming plays a vital role in glioblastoma (GBM) progression and recurrence by producing enough energy for highly proliferating tumor cells. In addition, metabolic reprogramming is crucial for tumor growth and immune‐escape mechanisms. Epidermal growth factor receptor ( EGFR ) amplification and EGFR‐vIII mutation are often detected in GBM cells, contributing to the malignant behavior. This study aimed to investigate the functional role of the EGFR pathway on fatty acid metabolism remodeling and energy generation. Methods Clinical GBM specimens were selected for single‐cell RNA sequencing and untargeted metabolomics analysis. A metabolism‐associated RTK‐fatty acid‐gene signature was constructed and verified. MK‐2206 and MK‐803 were utilized to block the RTK pathway and mevalonate pathway induced abnormal metabolism. Energy metabolism in GBM with activated EGFR pathway was monitored. The antitumor effect of Osimertinib and Atorvastatin assisted by temozolomide (TMZ) was analyzed by an intracranial tumor model in vivo. Results GBM with high EGFR expression had characteristics of lipid remodeling and maintaining high cholesterol levels, supported by the single‐cell RNA sequencing and metabolomics of clinical GBM samples. Inhibition of the EGFR/AKT and mevalonate pathways could remodel energy metabolism by repressing the tricarboxylic acid cycle and modulating ATP production. Mechanistically, the EGFR/AKT pathway upregulated the expressions of acyl‐CoA synthetase short‐chain family member 3 (ACSS3), acyl‐CoA synthetase long‐chain family member 3 (ACSL3), and long‐chain fatty acid elongation‐related gene ELOVL fatty acid elongase 2 (ELOVL2) in an NF‐κB‐dependent manner. Moreover, inhibition of the mevalonate pathway reduced the EGFR level on the cell membranes, thereby affecting the signal transduction of the EGFR/AKT pathway. Therefore, targeting the EGFR/AKT and mevalonate pathways enhanced the antitumor effect of TMZ in GBM cells and animal models. Conclusions Our findings not only uncovered the mechanism of metabolic reprogramming in EGFR‐activated GBM but also provided a combinatorial therapeutic strategy for clinical GBM management.

DHFR/TYMS Are Positive Regulators of Glioma Cell Growth and Modulate Chemo-Sensitivity to Temozolomide.

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

FoxM1-mediated RFC5 Expression Promotes Temozolomide Resistance.

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy

IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT

Inhibition Of Elongation Factor-2 Kinase Augments The Antitumor Activity Of Temozolomide Against Glioma

Hypoxanthine Phosphoribosyl Transferase 1 Metabolizes Temozolomide to Activate AMPK for Driving Chemoresistance of Glioblastomas.

Dddr-01. Tumor Associated Macrophages Vis-À-Vis Tmz Resistance In Pten-Deficient Glioma

Temozolomide in Combination with Metformin Act Synergistically to Inhibit Proliferation and Expansion of Glioma Stem-Like Cells

Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway

A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma

The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma

miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma

Unveiling the Pharmacological Role of Human Deubiquitinating Enzymes in Temozolomide Response of Glioblastoma Cells

Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6 -methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen

Glioma-Astrocyte Connexin43 Confers Temozolomide Resistance Through Activation of the E2F1/ERCC1 Axis.

miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells

Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma

Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma

Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma